MSD® Inflammation Panel 3 (cyno) Kit

For quantitative determination in cynomolgus (cyno) serum and plasma

Alzheimer's Disease BioProcess Cardiac Cell Signaling Clinical Immunology Cytokines Growth Factors Hypoxia Immunogenicity Inflammation Metabolic Oncology Toxicology Vascular

Catalog Numbers

| Inflammation Panel 3 (cyno) Kit | | | |
|------------------------------------|-----------|--|--|
| Kit size | | | |
| 1 plate | K15191D-1 | | |
| 5 plates | K15191D-2 | | |
| 25 plates | K15191D-4 | | |

Ordering information


MSD Customer Service Phone: 1-301-947-2085 Fax: 1-301-990-2776 Email: CustomerService@ mesoscale.com

Company Address

MESO SCALE DISCOVERY® division of Meso Scale Diagnostics, LLC. 9238 Gaither Road Gaithersburg, MD 20877 USA

www.mesoscale.com®


For Research Use Only. Not for use in diagnostic procedures.



Non-human primates (NHPs) are often used in pre-clinical research related to HIV, teratology, stroke, xenotransplantation, and several inflammatory disease states. These efforts typically utilize NHPs as a second species in the late phases of drug discovery and development to assess the efficacy and safety of new drugs and their mechanism of action. To aid these efforts, MSD continues to develop assays to monitor the levels of critical inflammatory mediators such as MCP-1, NGAL, and TIMP-1. Increased levels of these markers may play a pivotal role in the pathogenesis of inflammatory diseases such as atherosclerosis, rheumatoid arthritis, and acute kidney injury. TIMP-1 and NGAL expression can indicate inflammatory action following infection, ischemia, and endotoxic insults to the endothelium and stromal matrix. MCP-1 is uniformly upregulated at these sites of vascular disease or injury and is one of the earliest cellular responses to atherogenesis. The assays were tested for sensitivity, specificity, spike recovery, dilution linearity, precision, accuracy, robustness, and sample handling. The panel is available on 96-well 4-spot plates. Representative data from assay development are presented below. Visit www.mesoscale.com for a complete listing of our products.

Assay Sensitivity

The following standard curves illustrate the dynamic range of the assays in the Inflammation Panel 3 (cyno) Kit.



| | MCP-1 | NGAL | TIMP-1 |
|-------------------------|---------|-------|--------|
| Average LLOD (ng/mL) | 0.00030 | 0.015 | 0.36 |

The lower limit of detection (LLOD) is a calculated concentration based on a signal 2.5 standard deviations above the background (zero calibrator blank). The LLOD shown above was calculated based on 21 runs.

MSD Advantage

- > **Multiplexing:** Multiple analytes can be measured in one well using typical sample volumes of 50 μL or less without compromising speed or performance
- Large dynamic range: Linear range of up to five logs enables the measurement of native levels of biomarkers in normal and diseased samples without multiple dilutions
- Minimal background: The stimulation mechanism (electricity) is decoupled from the signal (light)
- Simple protocols: Only labels near the electrode surface are detected, enabling assays with fewer washes
- Flexibility: Labels are stable, non-radioactive, and conveniently conjugated to biological molecules
- High sensitivity and precision: Multiple excitation cycles of each label enhance light levels and improve sensitivity





MSD Toxicology Assays

Spike Recovery

Normal cynomolgus monkey serum, EDTA plasma, and heparin plasma samples were diluted 25-fold then spiked with calibrators at multiple levels throughout the range of the assay. The average percent recovery shown below was calculated from samples with values above the LLOD. % Recovery=measured/expected*100

| | MCP-1 | | | NGAL | | | TIMP-1 | | |
|-----------------|---------------------------|-----------------------|---------|---------------------------|-----------------------|---------|---------------------------|-----------------------|---------|
| Sample Type | Spike Conc. (ng/mL) | Average % Recovery | % Range | Spike Conc. (ng/mL) | Average % Recovery | % Range | Spike Conc. (ng/mL) | Average % Recovery | % Range |
| Corum | 0.020 | 109 | 97–131 | 0.63 | 100 | 93-104 | 1.3 | 100 | 97–105 |
| Serum (N=10) | 0.080 | 96 | 85-103 | 2.5 | 99 | 85-106 | 5.0 | 103 | 92-110 |
| (N=10) | 0.32 | 92 | 80-100 | 10 | 100 | 86-107 | 20 | 98 | 87-106 |
| EDTA | 0.020 | 113 | 97–110 | 0.63 | 96 | 90-102 | 1.3 | 102 | 97-110 |
| Plasma | 0.080 | 101 | 99-104 | 2.5 | 103 | 101-105 | 5.0 | 108 | 104-112 |
| (N=5) | 0.32 | 98 | 94-103 | 10 | 106 | 102-111 | 20 | 113 | 109-117 |
| Heparin | 0.020 | 107 | 102-113 | 0.63 | 103 | 100-110 | 1.3 | 99 | 88-108 |
| Plasma | 0.080 | 100 | 99-103 | 2.5 | 100 | 94-106 | 5.0 | 100 | 90-116 |
| (N=5) | 0.32 | 94 | 87-100 | 10 | 97 | 94-102 | 20 | 92 | 78–100 |

Tested Samples

Normal cynomolgus monkey, EDTA plasma, and heparin plasma samples were tested at 25-fold dilutions with the Inflammation Panel 3 (cyno). Median and range of concentrations for each sample set are displayed below. Concentrations are corrected for sample dilution.

| Sample Type | Statistic | MCP-1 | NGAL | TIMP-1 |
|-------------------|--------------------|--------------|--------|-------------------------------|
| Serum | Median (ng/mL) | 0.083 | 14 | 347 |
| | Range (ng/mL) | 0.027-0.39 | 6.4-56 | 213–501 |
| | Number of Samples | 20 | 20 | 20 |
| | Samples above LLOD | 20 | 20 | 20 |
| EDTA Plasma | Median (ng/mL) | 0.047 | 7.6 | 90 |
| | Range (ng/mL) | 0.015-0.081 | 3.2-19 | 49–264 |
| | Number of Samples | 10 | 10 | 10 |
| | Samples above LLOD | 10 | 10 | 10 |
| Heparin Plasma | Median (ng/mL) | 0.036 | 7.2 | 48 |
| | Range (ng/mL) | 0.0092-0.092 | 1.5-48 | <llod-202< td=""></llod-202<> |
| | Number of Samples | 10 | 10 | 10 |
| | Samples above LLOD | 10 | 10 | 9 |

Precision

Controls were made by spiking calibrator into cynomolgus monkey serum at levels throughout the range of the assay. Analyte levels were measured using a minimum of 2 replicates on 15 runs over 11 days. Average intra-run %CV is the average %CV of the control replicates on an individual run. Inter-run %CV is the variability of controls across 15 runs.

| | Control | Runs | Average Conc. (ng/mL) | Average Intra-run %CV | Inter-run %CV |
|--------|---------|------|-----------------------------|-----------------------------|------------------|
| | High | 15 | 0.28 | 4.6 | 10.3 |
| MCP-1 | Mid | 15 | 0.028 | 3.3 | 5.9 |
| | Low | 15 | 0.0023 | 3.7 | 7.3 |
| NGAL | High | 15 | 9.0 | 3.2 | 9.2 |
| | Mid | 15 | 1.2 | 2.9 | 6.5 |
| | Low | 15 | 0.14 | 4.1 | 11.0 |
| TIMP-1 | High | 15 | 18 | 2.4 | 8.6 |
| | Mid | 15 | 6.8 | 2.9 | 8.1 |
| | Low | 15 | 0.91 | 6.0 | 11.9 |

MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, WWW.MESOSCALE.COM, MSD, MSD (DESIGN), DISCOVERY WORKBENCH, QUICKPLEX, MULTI-ARRAY, MULTI-SPOT, SULFO-TAG, SECTOR, SECTOR HTS, SECTOR PR, 4-SPOT (DESIGN) and SPOT THE DIFFERENCE are trademarks and/or service marks of Meso Scale Diagnostics, LLC.

